Home/Pipeline/RCT1100

RCT1100

Primary Ciliary Dyskinesia (PCD)

Phase 1Active

Key Facts

Indication
Primary Ciliary Dyskinesia (PCD)
Phase
Phase 1
Status
Active
Company

About PARI Pharma

PARI Pharma is a long-established, privately-held German company that has evolved into a leading partner for inhaled drug development, leveraging its proprietary eFlow mesh nebulizer technology. It operates as a contract development and manufacturing organization (CDMO) for respiratory therapeutics, offering end-to-end support from device customization to regulatory strategy and commercial supply. With over 20 years of experience in mesh nebulization, PARI supports a robust pipeline of partner programs, including several in late-stage clinical trials, targeting complex respiratory diseases like non-CF bronchiectasis, pulmonary fibrosis, and bronchiolitis obliterans syndrome.

View full company profile

Therapeutic Areas

Other Primary Ciliary Dyskinesia (PCD) Drugs

DrugCompanyPhase
Idrevloride (P-1037)Parion SciencesPhase 2